Selinexor-d5

Selinexor-d5 (KPT-330-d5) isthe deuterium labeled Selinexor (HY-17536) . Selinexor (KPT-330), an analog of KPT-185, is an orally active and selective CRM1 inhibitor[1][2].

Product Specifications

Product Name Alternative

KPT-330-d5

UNSPSC

12352005

Target

CRM1; Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Others

Field of Research

Cancer

Smiles

O=C(NNC1=NC([2H])=C([2H])N=C1[2H])/C([2H])=C([2H])\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2

Molecular Formula

C17H6D5F6N7O

Molecular Weight

448.34

References & Citations

[1]Etchin J, et al. KPT-330 inhibitor of CRM1 (XPO1) -mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013 Apr;161 (1) :117-27. |[2]Tai YT, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan;28 (1) :155-65.